Prostate Cancer Diagnostics Market Growth Outlook Through 2024-2033

Overview and Scope
Prostate cancer diagnostics refers to the process of determining and verifying the presence of prostate cancer using diagnostic testing and medical evaluations with the purpose of evaluating the status and severity of the illness and directing treatment choices. It is commonly used to treat prostatic adenocarcinoma, transitional cell carcinomas, and neuroendocrine tumors.

Sizing and Forecast
The prostate cancer diagnostics market size has grown rapidly in recent years. It will grow from $3.86 billion in 2023 to $4.4 billion in 2024 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to increasing aging population, advancements in medical imaging, rising awareness and screening programs, public health initiatives, improved biopsy techniques.

The prostate cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $7.11 billion in 2028 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to integration of artificial intelligence (ai), growth of telemedicine in cancer screening, advancements in genomic profiling, patient-centric approaches, multiparametric mri for diagnosis. Major trends in the forecast period include liquid biopsy technologies, technological advances in biomarker detection, clinical research and development, digital pathology integration, emergence of multiplex biomarker assays.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/prostate-cancer-diagnostics-global-market-report

Segmentation & Regional Insights
The prostate cancer diagnostics market covered in this report is segmented –

1) By Products: Instruments, Reagents And Consumables, Accessories
2) By Test Type: Preliminary Tests, Confirmatory Tests
3) By Prostate Cancer: Squamous Cell Cancer, Small Cell Carcinoma, Transitional Cell Cancer, Prostatic Adenocarcinoma, Ductal Adenocarcinoma, Small Cell Prostate Cancer, Acinar Adenocarcinoma
4) By Peer Groups: Adult, Pediatric, Geriatrics
5) By End User: Hospitals, Independent Diagnostic Laboratories, Cancer Research Institutes, Other End-Users

North America was the largest region in the prostate cancer diagnostics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=12003&type=smp

Major Driver Impacting Market Growth
The increasing prevalence of prostate cancer is expected to propel the growth of the prostate cancer diagnostics market going forward. Prostate cancer is a condition in which cancer arises in the prostate gland, a component of the male and female reproductive systems. Prostate cancer diagnostics helps patients to diagnose the disease early with various tests, including prostate-specific antigen (PSA) testing and sophisticated imaging techniques. For instance, in January 2023, according to the American Cancer Society (ACS), a US-based non-profit organization dedicated to eliminating cancer, approximately 288,300 new cases of prostate cancer and 34,700 deaths attributed to prostate cancer in 2023. Therefore, increasing prevalence of prostate cancer is expected to propel the growth of the prostate cancer diagnostics market.

Key Industry Players

Major companies operating in the prostate cancer diagnostics market report are F. Hoffman-La Roche AG, Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Becton Dickinson and Company, Agilent Technologies Inc., Hologic Inc., Biomerieux SA, Beckman Coulter Inc., Qiagen N.V., EXACT Sciences Corporation, Diasorin S.P.A., OPKO Health Inc., Myriad Genetics Inc., Cepheid Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., GRAIL Inc., Fujirebio Diagnostics Inc., Ambry Genetics Corporation, MDxHealth SA, Biocept Inc., Blue Earth Therapeutics Ltd., Exosome Diagnostics Inc., Eurolyser Diagnostica GmbH, Dana-Farber Cancer Institute, Vyant Bio Inc., Cellanyx Diagnostics Inc., A3P Biomedical AB

The prostate cancer diagnostics market report table of contents includes:

1. Executive Summary
2. Prostate Cancer Diagnostics Market Characteristics
3. Prostate Cancer Diagnostics Market Trends And Strategies
4. Prostate Cancer Diagnostics Market – Macro Economic Scenario
5. Global Prostate Cancer Diagnostics Market Size and Growth
.
.
.
31. Prostate Cancer Diagnostics Market Other Major And Innovative Companies
32. Global Prostate Cancer Diagnostics Market Competitive Benchmarking
33. Global Prostate Cancer Diagnostics Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Prostate Cancer Diagnostics Market
35. Prostate Cancer Diagnostics Market Future Outlook and Potential Analysis
36.Appendix

Explore the trending research reports from TBRC:

Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model